Endeavor Health
Condition: Prostate cancer Intervention: Biopsy and inherited risk assessment
Inherited genetic changes, including rare pathogenic mutations (RPMs) in several major genes and single nucleotide polymorphisms (SNPs)-based genetic risk scores (GRS) have been consistently associated with prostate cancer (PCa) risk. Furthermore, results from retrospective analyses of two clinical trials (PCPT and REDUCE) and biopsy cohorts revealed Caucasian men with higher GRS are 1) more likely to have positive biopsy and 2) have higher number of positive biopsy cores. These findings suggest inherited risk assessment may have clinical utility in identifying men who have a higher likelihood…
Inclusion Criteria: * Consecutive patients undergoing prostate biopsy for detection of prostate cancer * Aged 40 to 69 years * Four ethnicity groups (Caucasian, African Americans, East Asians, Latinos) * PSA between 2.5-10 ng/mL Exclusion Criteria: * Previous diagnosis of prostate cancer. * Ethnicity outside the inclusion criterion (including mixed ethnicity). * Any prior PSA test result outside the range of inclusion criterion.
The trial is to observe whether inherited risk, including rare pathogenic mutations (RPMs) in several major genes and SNPs-based genetic risk scores (GRS), is correlated with prostate cancer detection rate from diagnostic prostate biopsy.
Arctuva estimate
Verify or correct the compensation shown for this listing.